Contraception with Estradiol Valerate and Dienogest: Adherence to the Method

Overview

Journal Open Access J Contracept

Publisher Dove Medical Press

Specialty Reproductive Medicine

Date 2019 Jun 14

PMID 31191048

Authors

Franca Fruzzetti

Anna Maria Paoletti

Tiziana Fidecicchi

Giulia Posar

Riccardo Giannini

Marco Gambacciani

Affiliations

Soon will be listed here.

Abstract

The aim of the study was to examine the discontinuation rate of hormonal contraception with estradiol valerate (E2V) and dienogest (DNG). We collected data at the Family Planning Clinics of the Departments of Obstetrics and Gynecology of Pisa and Cagliari. We included in the analysis 354 consecutive women using oral contraceptive pills containing E2V and DNG. We analyzed the rate and the reason for discontinuation, classifying the reasons in 5 categories: 1) minor side effects, 2) adverse events, 3) other events not directly caused by the drug or conditions for which the pill could represent a risk factor, 4) no compliance with the method and 5) no further need. Of the 354 women examined, 50.8% had discontinued E2V/DNG pill. Excluding women who stopped the pill because of no further need (10.5%), 27.4% discontinued because of minor side effects, 1.7% discontinued for adverse events, 9.9% because of other events not directly caused by the drug or conditions for which the pill could represent a risk factor and 1.4% because of difficulties with compliance. Irregular bleedings were the main reasons reported for discontinuation. The time to discontinuation for irregular bleedings was significantly (<0.02) longer in adults than in adolescents and slightly but not significantly longer in women who received information about this possible effect. Unacceptable cycle control was the principal cause of discontinuation of pill with E2V and DNG. An appropriate information about this possible effect may improve adherence to this combined oral contraceptive.

References

Kuhl H . Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005; 8 Suppl 1:3-63. DOI: 10.1080/13697130500148875. View

Ahrendt H, Makalova D, Parke S, Mellinger U, Mansour D . Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception. 2009; 80(5):436-44. DOI: 10.1016/j.contraception.2009.03.018. View

Palacios S, Wildt L, Parke S, Machlitt A, Romer T, Bitzer J . Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol. 2009; 149(1):57-62. DOI: 10.1016/j.ejogrb.2009.11.001. View

Fruzzetti F, Bitzer J . Review of clinical experience with estradiol in combined oral contraceptives. Contraception. 2009; 81(1):8-15. DOI: 10.1016/j.contraception.2009.08.010. View

Gaussem P, Alhenc-Gelas M, Thomas J, Bachelot-Loza C, Remones V, Ali F . Haemostatic effects of a new combined oral contraceptive, nomegestrol acetate/17β-estradiol, compared with those of levonorgestrel/ethinyl estradiol. A double-blind, randomised study. Thromb Haemost. 2011; 105(3):560-7. DOI: 10.1160/TH10-05-0327. View

Klipping C, Duijkers I, Parke S, Mellinger U, Serrani M, Junge W . Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Drugs R D. 2011; 11(2):159-70. PMC: 3585947. DOI: 10.2165/11591200-000000000-00000. View

Junge W, Mellinger U, Parke S, Serrani M . Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study. Clin Drug Investig. 2011; 31(8):573-584. DOI: 10.2165/11590220-000000000-00000. View

Mansour D, Verhoeven C, Sommer W, Weisberg E, Taneepanichskul S, Melis G . Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. Eur J Contracept Reprod Health Care. 2011; 16(6):430-43. PMC: 3233274. DOI: 10.3109/13625187.2011.614029. View

Jensen J, Parke S, Mellinger U, Serrani M, Mabey Jr R . Hormone withdrawal-associated symptoms: comparison of oestradiol valerate/dienogest versus ethinylestradiol/norgestimate. Eur J Contracept Reprod Health Care. 2013; 18(4):274-83. DOI: 10.3109/13625187.2013.785516. View

10.

Macias G, Merki-Feld G, Parke S, Mellinger U, Serrani M . Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J Obstet Gynaecol. 2013; 33(6):591-6. DOI: 10.3109/01443615.2013.800851. View

11.

Lindberg U, Crona N, Stigendal L, TEGER-NILSSON A, Silfverstolpe G . A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost. 1989; 61(1):65-9. View

12.

Briggs P, Serrani M, Vogtlander K, Parke S . Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a.... Int J Womens Health. 2016; 8:477-487. PMC: 5029837. DOI: 10.2147/IJWH.S107586. View

13.

Fruzzetti F, Perini D, Fornaciari L, Russo M, Bucci F, Gadducci A . Discontinuation of modern hormonal contraceptives: an Italian survey. Eur J Contracept Reprod Health Care. 2016; 21(6):449-454. DOI: 10.1080/13625187.2016.1234598. View

14.

GURPIDE E, Marks C . Influence of endometrial 17 beta-hydroxysteroid dehydrogenase activity on the binding of estradiol to receptors. J Clin Endocrinol Metab. 1981; 52(2):252-5. DOI: 10.1210/jcem-52-2-252. View